Overall, the evidence regarding the clinical effectiveness of cannabinoids for the treatment of PTSD is limited. The one included study concluded that the synthetic cannabinoid nabilone was effective in treating patients with PTSD who were experiencing treatment-resistant nightmares. Approximately 70% of patients enrolled in the trial experienced either a reduction in frequency or intensity, or complete cessation of nightmares while taking nabilone. None of the three evidence-based guidelines discussed the use of cannabinoids in the management of PTSD. All three of the guidelines recommended the use of CBT or SSRIs for the treatment of patients with PTSD.
Overall, the evidence regarding the clinical effectiveness of cannabinoids for the treatment of PTSD is limited. The paucity of information may wish to be considered when making decisions regarding coverage of cannabinoids or the clinical use of cannabinoids for PTSD.